Mediwound Ltd (MDWD)

$19.8

+0.43

(+2.22%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $19.11
    $19.88
    $19.80
    downward going graph

    3.48%

    Downside

    Day's Volatility :3.87%

    Upside

    0.4%

    downward going graph
  • $7.10
    $24.00
    $19.80
    downward going graph

    64.14%

    Downside

    52 Weeks Volatility :70.42%

    Upside

    17.5%

    downward going graph

Returns

PeriodMediwound LtdIndex (Russel 2000)
3 Months
6.2%
0.0%
6 Months
51.33%
0.0%
1 Year
108.39%
0.0%
3 Years
-28.68%
-20.2%

Highlights

Market Capitalization
180.2M
Book Value
$2.51
Earnings Per Share (EPS)
-1.36
PEG Ratio
-0.07
Wall Street Target Price
29.75
Profit Margin
-64.24%
Operating Margin TTM
-75.22%
Return On Assets TTM
-14.19%
Return On Equity TTM
-45.14%
Revenue TTM
19.9M
Revenue Per Share TTM
2.15
Quarterly Revenue Growth YOY
30.7%
Gross Profit TTM
13.2M
EBITDA
-14.1M
Diluted Eps TTM
-1.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.59
EPS Estimate Next Year
-1.93
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Mediwound Ltd(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 50.25%

Current $19.80
Target $29.75

Company Financials

FY18Y/Y Change
Revenue
3.4M
↑ 36.26%
Net Income
-1.1M
↓ 95.23%
Net Profit Margin
-31.08%
↑ 856.3%
FY19Y/Y Change
Revenue
31.8M
↑ 834.7%
Net Income
3.7M
↓ 451.75%
Net Profit Margin
11.7%
↑ 42.78%
FY20Y/Y Change
Revenue
21.8M
↓ 31.54%
Net Income
-9.6M
↓ 358.23%
Net Profit Margin
-44.12%
↓ 55.82%
FY21Y/Y Change
Revenue
23.8M
↑ 9.19%
Net Income
-13.6M
↑ 41.14%
Net Profit Margin
-57.03%
↓ 12.91%
FY22Y/Y Change
Revenue
26.5M
↑ 11.5%
Net Income
-19.6M
↑ 44.63%
Net Profit Margin
-73.97%
↓ 16.94%
FY23Y/Y Change
Revenue
18.7M
↓ 29.48%
Net Income
-6.7M
↓ 65.73%
Net Profit Margin
-35.94%
↑ 38.03%
Q4 FY22Q/Q Change
Revenue
11.6M
↑ 100.21%
Net Income
-7.5M
↑ 77.59%
Net Profit Margin
-64.18%
↑ 8.18%
Q1 FY23Q/Q Change
Revenue
3.8M
↓ 67.3%
Net Income
-3.7M
↓ 50.48%
Net Profit Margin
-97.21%
↓ 33.03%
Q2 FY23Q/Q Change
Revenue
4.8M
↑ 25.64%
Net Income
916.0K
↓ 124.8%
Net Profit Margin
19.19%
↑ 116.4%
Q3 FY23Q/Q Change
Revenue
4.8M
↑ 0.06%
Net Income
-2.2M
↓ 339.74%
Net Profit Margin
-45.98%
↓ 65.17%
Q4 FY23Q/Q Change
Revenue
5.3M
↑ 11.77%
Net Income
-1.7M
↓ 20.63%
Net Profit Margin
-32.65%
↑ 13.33%
Q1 FY24Q/Q Change
Revenue
5.0M
↓ 7.01%
Net Income
-9.7M
↑ 458.18%
Net Profit Margin
-195.99%
↓ 163.34%
FY18Y/Y Change
Total Assets
35.3M
↓ 20.07%
Total Liabilities
26.3M
↓ 23.79%
FY19Y/Y Change
Total Assets
40.6M
↑ 15.06%
Total Liabilities
25.4M
↓ 3.36%
FY20Y/Y Change
Total Assets
31.1M
↓ 23.45%
Total Liabilities
23.8M
↓ 6.38%
FY21Y/Y Change
Total Assets
19.7M
↓ 36.45%
Total Liabilities
24.3M
↑ 2.22%
FY22Y/Y Change
Total Assets
50.0M
↑ 153.32%
Total Liabilities
39.1M
↑ 60.74%
FY23Y/Y Change
Total Assets
66.5M
↑ 32.88%
Total Liabilities
27.2M
↓ 30.47%
Q4 FY22Q/Q Change
Total Assets
50.0M
↑ 74.97%
Total Liabilities
39.1M
↑ 45.2%
Q1 FY23Q/Q Change
Total Assets
68.7M
↑ 37.29%
Total Liabilities
35.4M
↓ 9.55%
Q2 FY23Q/Q Change
Total Assets
64.4M
↓ 6.26%
Total Liabilities
29.4M
↓ 16.76%
Q3 FY23Q/Q Change
Total Assets
67.0M
↑ 4.12%
Total Liabilities
34.0M
↑ 15.39%
Q4 FY23Q/Q Change
Total Assets
66.5M
↓ 0.83%
Total Liabilities
27.2M
↓ 19.96%
Q1 FY24Q/Q Change
Total Assets
62.4M
↓ 6.14%
Total Liabilities
39.2M
↑ 44.11%
FY18Y/Y Change
Operating Cash Flow
-12.2M
↓ 26.14%
Investing Cash Flow
-17.0M
↓ 3999.31%
Financing Cash Flow
46.0K
↓ 99.8%
FY19Y/Y Change
Operating Cash Flow
8.3M
↓ 168.2%
Investing Cash Flow
-6.9M
↓ 59.52%
Financing Cash Flow
-1.0M
↓ 2286.96%
FY20Y/Y Change
Operating Cash Flow
-6.9M
↓ 183.18%
Investing Cash Flow
17.4M
↓ 352.07%
Financing Cash Flow
-629.0K
↓ 37.48%
FY21Y/Y Change
Operating Cash Flow
-8.9M
↑ 29.31%
Investing Cash Flow
3.5M
↓ 79.59%
Financing Cash Flow
-1.1M
↑ 66.93%
FY22Y/Y Change
Operating Cash Flow
-11.9M
↑ 33.3%
Investing Cash Flow
-481.0K
↓ 113.56%
Financing Cash Flow
35.8M
↓ 3506.1%
Q4 FY22Q/Q Change
Operating Cash Flow
2.0M
↓ 143.8%
Investing Cash Flow
2.4M
↓ 3095.0%
Financing Cash Flow
14.6M
↑ 24.29%
Q1 FY23Q/Q Change
Operating Cash Flow
652.0K
↓ 67.4%
Investing Cash Flow
-7.4M
↓ 410.64%
Financing Cash Flow
24.3M
↑ 65.69%

Technicals Summary

Sell

Neutral

Buy

Mediwound Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mediwound Ltd
Mediwound Ltd
27.27%
51.33%
108.39%
-28.68%
-14.33%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mediwound Ltd
Mediwound Ltd
NA
NA
-0.07
-2.59
-0.45
-0.14
NA
2.51
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mediwound Ltd
Mediwound Ltd
Buy
$180.2M
-14.33%
NA
-64.24%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Mediwound Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.33M → 4.96M (in $), with an average decrease of 7.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.74M → -9.72M (in $), with an average decrease of 458.2% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 215.2%

Institutional Holdings

  • Rosalind Advisors, Inc.

    5.23%

  • Yelin Lapidot Holdings Management Ltd

    3.10%

  • Dafna Capital Management LLC

    2.03%

  • Uniplan Investment Counsel, Inc.

    1.57%

  • Essex Investment Management Company, LLC

    1.43%

  • Wells Fargo & Co

    1.41%

Company Information

mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and

Organization
Mediwound Ltd
Employees
100
CEO
Ms. Hani Luxenburg
Industry
Health Technology

Discover More

FAQs